INTRODUCTION {#S1}
============

Estrogens are generally perceived to be inhibitory in male development or at least to antagonize androgen action^[@R1]^. Androgen action is essential for the acquisition of a normal male phenotype. Following the early steps of bipotential gonad formation and testis determination, androgens are required for the stabilization of the Wolffian duct system and its differentiation into the epididymides, vasa deferentia, and seminal vesicles. Their action is also critical for proper virilization of the external genitalia and migration of the testes through the inguinal canal into the scrotum^[@R2]^. The dependence of the masculinization of the reproductive system on androgen, however, renders this process inherently susceptible to destabilization by factors interfering with hormone synthesis, metabolism, or action. Such disturbances represent significant etiological determinants that potentially contribute to the high prevalence of human masculinization disorders, such as hypospadias (male urethral dysmorphogenesis) and cryptorchidism (failure of testicular descent).

Epidemiological studies provide links between inappropriate estrogen exposure and increased incidence of reproductive abnormalities in men (for review^[@R3],[@R4]^). Similarly, reproductive tract lesions, such as cryptorchidism and penile defects, were present in male mice after pre- and neonatal exposure to the potent nonsteroidal synthetic estrogen, diethylstilbestrol^[@R5]--[@R8]^. Furthermore, transgenic male mice overexpressing the enzyme aromatase, necessary for the conversion of androgens to estrogens, display several genital abnormalities, including undescended testes, subtle effects on penile development, and spermatogenic arrest^[@R9]^.

The tight interrelationship between the androgens and estrogens working together to regulate the differentiation of the male reproductive system relies on the balance between androgen and estrogen action, rather than on the absolute circulating concentrations of these hormones. Any change in this homeostasis may disturb the internal milieu required for normal development and function of the male genital tract and may translate into a wide range of genitourinary disorders that can subsequently affect normal fertility.

RESULTS {#S2}
=======

A terminal Xq28 copy number gain encompassing the *VAMP7* gene in children born with masculinization disorders {#S3}
--------------------------------------------------------------------------------------------------------------

We used a clinically validated comparative genomic hybridization microarray platform to analyze DNA from 116 children presenting with idiopathic cases of 46, XY disorders of sexual development (DSD) including anomalies of testicular descent and defects of penile morphogenesis^[@R10]^. Structural DNA variation was highlighted as a potential underlying etiology for human disorders of sexual development, since frequent submicroscopic gains and losses of DNA segments were detected and strongly associated with defective urogenital traits^[@R10]^. Among the clinically significant imbalances identified, an identical copy number gain at the distal tip of the long arm of Xq28 was noted in two unrelated patients ([Fig. 1a--b](#F1){ref-type="fig"} and [Supplemental Fig. S1a--b](#SD1){ref-type="supplementary-material"}). One child had bilateral cryptorchidism with a right inguinal testis and a left intra-abdominal gonad. The second child presented with midscrotal hypospadias with chordee and penoscrotal transposition. CGH array analysis of DNA from unaffected parents revealed the *de novo* occurrence of the terminal Xq28 gain ([Supplemental Fig. S1c--d](#SD1){ref-type="supplementary-material"}). This structural variant was secondarily confirmed by FISH analysis ([Fig. 1c](#F1){ref-type="fig"}). When a two-tailed Fisher's exact test was used, this copy number change was found to be more frequent in subjects presenting with congenital genitourinary defects (2 out of 116) than in control individuals without urogenital abnormalities (*n* = 8,951) run on the same array CGH platform (*P* = 2.2×10^−3^). While the Xq28 region had contiguous coverage on the microarray, the distal BAC clone RP11-479B17 was the only segment showing a copy number gain ([Supplemental Fig. S1a--b](#SD1){ref-type="supplementary-material"}). The maximal size of the defect exclusively included the pseudoautosomal region 2 (PAR2) while the minimal critical interval (RP11-479B17) solely encompassed *VAMP7* ([Supplemental Fig. S1e](#SD1){ref-type="supplementary-material"}). The published literature reveals the presence of additional patients who presented with syndromic cryptorchidism and/or micropenis among their clinical features together with larger Xq28 terminal duplications that also encompassed *VAMP7* ([Fig. 1d](#F1){ref-type="fig"} and [Supplemental Table 1](#SD1){ref-type="supplementary-material"}).

On the basis of these observations, we hypothesized that Xq28 region and, more specifically, *VAMP7* duplication play a role in human disorders of masculinization of the urogenital tract. *VAMP7* is a highly conserved gene^[@R11]^ that encodes for a transmembrane protein belonging to the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) family localized in late endosomes and lysosomes. VAMP7 is required for (i) heterotypic fusion of late endosomes with lysosomes and homotypic lysosomal fusion^[@R12]--[@R14]^, (ii) calcium-regulated lysosomal exocytosis^[@R15]^, and (iii) focal exocytosis of late endocytic vesicles during phagosome formation^[@R16],[@R17]^. Quantitative PCR analysis of *VAMP7* copy number in the genome of an additional cohort of 180 individuals presenting with isolated hypospadias (*n* = 83), cryptorchidism (*n* = 79), or both urogenital conditions (*n* = 18) identified one additional case of isolated inguinal cryptorchidism and one patient with glandular hypospadias and chordee. Both bore a *VAMP7* copy gain ([Supplemental Fig. S2a](#SD1){ref-type="supplementary-material"}). A second independent replication study of primary cultures of human genital skin fibroblasts from 28 subjects with congenital genitourinary defects revealed 1 instance of mid-shaft hypospadias with a copy number gain of *VAMP7* (3.6%) ([Supplemental Fig. S2b](#SD1){ref-type="supplementary-material"}), convincingly supporting the association of *VAMP7* genomic gains with developmental disorders of the human genitourinary tract.

*VAMP7* is expressed in the human and mouse genital tract {#S4}
---------------------------------------------------------

VAMP7 protein was detected in cytoplasmic lysates from human fetal testes and ovaries ([Fig. 2a](#F2){ref-type="fig"}). At adult stages, *VAMP7* mRNA levels were detected throughout the human male genital tract including the testes, epididymides, seminal vesicles, and prostatic and penile tissues ([Fig. 2b](#F2){ref-type="fig"}). A punctuate pattern of VAMP7 staining was present in the Sertoli cells, as well as in the germ cells of the seminiferous tubules of human adult testes with histologically normal spermatogenesis ([Fig. 2c](#F2){ref-type="fig"}). The cytoplasm of Leydig cells also contained VAMP7-positive immunoreactive staining ([Fig. 2c](#F2){ref-type="fig"}). In the adult human external genitalia, *VAMP7* was strongly expressed in the urethral epithelium ([Fig. 2d](#F2){ref-type="fig"}). Moreover, the genital mesenchyme, including corpus cavernosa and the androgen-dependent penile spines of the preputial epithelium, showed significant levels of VAMP7 protein ([Fig. 2e](#F2){ref-type="fig"}). Similarly, fetal testes and developing genital tubercles in mouse embryos at gestational day 16.5 were positively stained for VAMP7 ([Fig. 2f--g](#F2){ref-type="fig"}). Thus, VAMP7 mRNA and protein are present in the human and murine genitourinary tract during development and at maturity.

Increased gene dosage of VAMP7 results in defects of testicular descent and morphogenesis of external genitalia in mice {#S5}
-----------------------------------------------------------------------------------------------------------------------

We sought to investigate *in vivo* the impact of genetically elevated VAMP7 levels on genitourinary development and reproductive physiology. A mouse model that expresses human *VAMP7* under its endogenous regulatory sequences was produced to recapitulate the genetic gain observed in patients. Mutant mice were generated through microinjection of a 159-kilobase linearized bacterial artificial chromosome (BAC; clone RP11-479B17) including the human *VAMP7* gene, into fertilized oocytes of FVB mice. Two independent *VAMP7* founder lines, 7 and 21, were obtained. BAC transgenic mice were viable and had normal growth and lifespan. Western blot analysis using an antibody that specifically recognizes the human VAMP7 protein confirmed the expression of the transgene in the testes of mutant mice ([Supplemental Fig. S3a](#SD1){ref-type="supplementary-material"}). Using primers that recognize both human and mouse transcripts, we quantified mRNA levels of *VAMP7* by qRT-PCR in the two lines (21 and 7) and found them to be only 2 to 3 times higher than the messenger levels of the endogenous *Vamp7* in WT mice ([Fig. 3a](#F3){ref-type="fig"}). Throughout the adult and fetal testes and external genitalia, the spatial expression pattern of the transgene mirrored that of the endogenous product in the wild-type animals and localized to cytoplasmic compartments as expected ([Fig. 3b](#F3){ref-type="fig"}). A parallel study of the two transgenic lines controlled for potential insertion effects. Data from strain 7 are presented when identical outcomes were obtained for both lines (for line 21-see [Supplemental Fig. S4](#SD1){ref-type="supplementary-material"}).

Examination of individually-housed *VAMP7* adult male mice revealed a high incidence of cryptorchid testes (87.5%; 7 out of 8 mice), either bilateral (85.7% for strain 7 and 57.2% for strain 21) or unilateral (14.3% for strain 7 and 42.8% for strain 21) ([Fig. 3c](#F3){ref-type="fig"}). Testes were considered (i) "scrotal" in location if they had to be pulled out of the scrotal sac. (ii) "inguinal" when superior to the scrotum but inferior to the bladder at the inguinal ring, or (iii) "low abdominal" or "high abdominal" respectively when they were at, or superior to, the level of the bladder. The testicular location in uni- or bilaterally cryptorchid *VAMP7* mutant mice was variable, predominantly inguinal in both strains (strain 7: 7.1% scrotal, 64.3% inguinal, and 28.6% low abdominal; strain 21: 21.4% scrotal, 42.9% inguinal, and 35.7% low abdominal) ([Fig. 3d](#F3){ref-type="fig"}). Importantly, none of the cryptorchid gonads were located in a high intra-abdominal position ([Fig. 3d--e](#F3){ref-type="fig"}), implying that the inguino-scrotal, androgen-dependent phase of testicular descent was defective in *VAMP7* BAC mice. Examination of the gubernaculum, a mesenchymal tissue connecting the fetal testis to the developing scrotum, revealed a slightly feminized appearance with a thinner and elongated gubernacular cord connected to the lower cauda epididymis, as compared to the rudimentary gonadal ligament in wild-type male siblings ([Fig. 3f](#F3){ref-type="fig"}). Interestingly, thin and elongated gubernaculum cords were seen previously in estrogen-treated mouse embryos^[@R18]--[@R21]^.

Histological analysis of *VAMP7* mutant genital tubercles revealed variable penile defects ([Fig. 3g](#F3){ref-type="fig"}). Half of the analyzed male transgenic embryos had normally developed genital tubercles with the ventral epithelial surfaces forming a closed urethral groove where epithelial surfaces fused to create the urethral seam and resulted in a true urethra. However, 16.7% (1 out of 6) of them exhibited hypospadias, a significant anomaly of the ventral urethral tube closure ([Fig. 3g](#F3){ref-type="fig"}). Underdeveloped os penis, abnormalities of the epithelial-lined prepuce housing the penis, and a reduction in the thickness of the tunica albuginea capsule surrounding the corpora cavernosa were observed in 33.3% (2 out of 6) of *VAMP7* BAC male embryos ([Fig. 3g](#F3){ref-type="fig"}). Importantly, many of the penile defects in *VAMP7* BAC animals resembled those observed following the prenatal or neonatal administration of estrogenic compounds in male mice^[@R6]--[@R8]^. Furthermore, anogenital distance tended to decrease in mutant *VAMP7* male mice ([Fig. 3h](#F3){ref-type="fig"}), but, more strikingly, penile length was significantly less in all adult transgenic animals than in their wild-type littermates ([Fig. 3i](#F3){ref-type="fig"}).

Thus, increased levels of *VAMP7* expression in the mouse male genitourinary tract mimicked the urogenital phenotypic traits observed in patients with *VAMP7* copy number gain, i.e. cryptorchidism, hypospadias and micropenis. The *VAMP7* BAC mouse models strongly suggest a causative link of VAMP7 duplication to congenital genitourinary defects in humans.

VAMP7 overexpression modestly alters androgen receptor action {#S6}
-------------------------------------------------------------

Since a *VAMP7* genomic defect was present in males presenting with cryptorchidism, hypospadias, or micropenis, and since normal androgen action is crucial for penile development and testicular descent, we asked whether elevated levels of VAMP7 interfere with androgen action. To assess the impact of VAMP7 on androgen receptor (AR) transcriptional activity, we used a cell-culture-based assay using a firefly luciferase reporter gene driven by an androgen responsive element (*ARE*) of the *PSA* promoter. Interestingly, ligand-dependent AR transcriptional activity was suppressed by 60% with VAMP7 overexpression ([Fig. 4a](#F4){ref-type="fig"}). This observed inhibition was not a result of a decrease of AR protein levels ([Supplemental Fig. S3b](#SD1){ref-type="supplementary-material"}). Physical co-presence of VAMP7 and AR in the same protein complexes was shown by co-immunoprecipitation assays, suggesting possible functional interactions between these two proteins ([Fig. 4b](#F4){ref-type="fig"}). Since VAMP7 is involved in cellular sorting^[@R12],[@R13],[@R22]^, we questioned whether VAMP7 overexpression alters the subcellular localization of the androgen receptor at the time of ligand-dependent stimulation. Immunofluorescent staining after transient transfection of the androgen receptor and/or VAMP7 in the presence or absence of dihydrotestosterone revealed the co-localization of VAMP7 and AR in the cytoplasm upon DHT administration ([Fig. 4c](#F4){ref-type="fig"}), implying a failure of efficient translocation of AR to the nucleus despite the presence of the ligand. Since VAMP7 localizes in the endosomes, we used RAB5A, a marker of early endosomes, to demonstrate a co-localization of AR and RAB5A in the presence of DHT ([Fig. 4c](#F4){ref-type="fig"}). To examine the existence of a potential mis-localization of AR *in vivo*, we then analyzed the cellular distribution of AR in the testes of *VAMP7* BAC mice, which express the transgene in ranges far below the high doses of our transfection conditions but similar to those in the human genomic gains. *In vivo*, AR was visible in the cytoplasm of few, but not all, positively stained cells of *VAMP7* BAC testes ([Fig. 4d](#F4){ref-type="fig"}), contrasting with its exclusive nuclear localization in the male gonads of wild type littermates ([Fig. 4d](#F4){ref-type="fig"}). We concluded that the observed mosaic pattern of AR subcellular distribution in *VAMP7* BAC testes reflects a partial interference of ligand-dependent shuttling of AR *in vivo*, likely due to VAMP7 overexpression.

Under these conditions, we examined AR recruitment to its genomic occupancy sites in the presence of increased *VAMP7* gene dosage. *In vivo* chromatin immunoprecipitation in testicular tissues of *VAMP7* transgenic mice was performed using the androgen-responsive element of several genes involved in AR signaling, including *Fkbp4, Mafb* and *Fkbp5*^[@R23]--[@R25]^. While a clear *in vivo* binding of AR was observed in wild-type testis, binding was significantly reduced in *VAMP7* transgenic male gonads ([Fig. 4e](#F4){ref-type="fig"}). Consistent with the observed AR occupancy, the immunoreactivity of the androgen-responsive genes, *Fkbp5* and *Mafb*^[@R26],[@R27]^ was lower in the fetal and adult genital tracts of *VAMP7* BAC male mice than in those of wild-type littermates ([Fig. 3f--g](#F3){ref-type="fig"}). The expression of other testicular androgen target genes such as *Rhox5, Drd4, Eppin (Spinlw), Tubb3*, and *Cldn11* was defined. With the exception of a significant decrease of *Cldn11* (encoding a tight junction protein at the blood-testis barrier), no drastic changes were observed in *VAMP7* BAC testes compared to those in WT animals ([Supplemental Fig. S3c](#SD1){ref-type="supplementary-material"}). Thus, the impact of VAMP7 on AR transcriptional activity, although apparent when examined in an *in vitro* cellular context, is only partial *in vivo*. This is reflected by subtle alterations in expression of selective AR target genes. Accordingly, other signaling pathways were likely to contribute to the phenotypic anomalies observed in the *VAMP7* BAC mice.

Elevated dosage of *VAMP*7 markedly enhances estrogen transcriptional action {#S7}
----------------------------------------------------------------------------

*In vivo*, the balance between androgen and estrogen receptor action, as opposed to androgen action alone, is an important factor for male reproductive tract development^[@R28]^. Consequently, further investigations focused on the impact of *VAMP7* overexpression on the estrogen signaling. With a classic estrogen-responsive element driving the expression of a luciferase reporter, an unexpected, massive and largely significant, synergistic transcriptional effect was observed when VAMP7 was co-transfected with estrogen receptor alpha (ESR1) in the presence of estradiol ([Fig. 5a](#F5){ref-type="fig"}). Under these conditions, VAMP7 increased the ligand-dependent protein concentration of ESR1 ([Fig. 5b](#F5){ref-type="fig"}), perhaps through protein stabilization or through the utilization of posttranslational mechanisms, since endogenous *ESR1* mRNA levels remained unaffected after a knockdown of *VAMP7* in the human testicular embryonic carcinoma cell line NT2/D1 ([Supplemental Fig. S3d](#SD1){ref-type="supplementary-material"}), or after VAMP7 overexpression in the testes of our transgenic mice ([Fig. 5](#F5){ref-type="fig"}). The potential for a functional interaction between VAMP7 and ESR1 was further substantiated by the fact that these two proteins were physically found in the same protein complexes ([Fig. 5c](#F5){ref-type="fig"}) and co-localized in identical sub-cellular compartments ([Supplemental Fig. S3e](#SD1){ref-type="supplementary-material"}).

To examine the *in vivo* functional interaction between VAMP7 and ESR1, we assessed gene expression of known players involved in the estradiol-mediated action in *VAMP7* BAC mice. While expression levels were unchanged for the estrogen-dependent coregulators, including p160 family (*Ncoa1, Ncoa2, Ncoa3), Crebbp, Kat2b, Med1, Ncor2, Carm1*, and the nuclear receptors *Ar* and *Esr1* ([Fig. 5d](#F5){ref-type="fig"} and [Supplemental Figure S4a](#SD1){ref-type="supplementary-material"}), a significant up-regulation of mRNA levels of three estrogen-responsive genes, including activating transcription factor 3 (*Atf3*), connective tissue growth factor (*Ctgf*), and cysteine-rich angiogenic inducer 61 (*Cyr61*) was observed in the testes of the *VAMP7* transgenic mice ([Fig. 5d](#F5){ref-type="fig"} and [Supplemental Figure S4a](#SD1){ref-type="supplementary-material"}). These observations are of key importance, as *ATF3, CTGF*, and *CYR61* are estrogen-responsive genes that are strongly up-regulated in hypospadias patients^[@R29]--[@R33]^. Moreover, variants of *ATF3* are associated with hypospadias in humans^[@R34],[@R35]^. Consistently, Atf3 protein levels were higher in fetal and adult testicular and penile tissues of *VAMP7* transgenic animals, than in wild-type littermates' tissues ([Fig. 5e](#F5){ref-type="fig"}). Conversely, selective knockdown of *VAMP7* in the human testicular embryonal carcinoma NT2/D1 cell line led to a significant decrease of *ATF3* gene expression ([Fig. 5f](#F5){ref-type="fig"}), confirming that VAMP7 is an important positive regulator of *ATF3* gene expression. Concomitantly, the expression levels of additional estrogen responsive genes were altered in the testis of VAMP7 mutant mice compared to wild-type gonads. Indeed, *Nrip1* mRNA levels, directly induced by estrogen receptor ction^[@R36]^, were higher in *VAMP7* mutant mice than in WT littermates ([Fig. 5d](#F5){ref-type="fig"}). The expression of *Cyp19a1*, which is down-regulated by estradiol in the testis^[@R37]^, was lower in the *VAMP7* transgenic mouse testes than in WT gonads ([Fig. 5d](#F5){ref-type="fig"} and [Supplemental Figure S4a](#SD1){ref-type="supplementary-material"}). Additionally, higher mRNA levels of estrogen sulfotransferase (*Sult1e1*) encoding an enzyme involved in the maintenance of the functional integrity of male-specific tissues against local estrogenic activity^[@R38]^, were observed in the testes of *VAMP7*-overexpressing mice than in WT animals ([Fig. 5d](#F5){ref-type="fig"} and [Supplemental Figure S4a](#SD1){ref-type="supplementary-material"}). In line with these *in vivo* data, estrogen receptor signaling was among the top pathways affected following the acute *VAMP7* knockdown in NT2/D1 cells, as revealed by the functional analysis of gene expression microarrays data by Ingenuity Pathway Analysis ([Fig. 5g](#F5){ref-type="fig"}).

Finally, the occurrence of inguinal hernias in some *VAMP7* BAC transgenic mice further supports our conclusions ([Fig. 5h](#F5){ref-type="fig"}), since this phenotypic trait is observed with estrogen overstimulation in animal models, *i.e*. after administration of estrogens in male rodents^[@R39],[@R40]^ and in aromatase overexpressing male mice^[@R9],[@R41]^.

Collectively, increased gene dosage of VAMP7, a SNARE protein, positively impacts ESR1 transcriptional activity ([Fig. 5i](#F5){ref-type="fig"}) and exerts a partial and inhibitory effect on AR action. ATF3, while positively induced by ESR1 action, acts as an AR corepressor by preventing its binding to target genes and inhibiting transcriptional activation^[@R42]^. This may explain the effects of *VAMP7* gain on the expression of several androgen-responsive genes such as *Cldn11, Fkbp5*, and *MafB*. The dual differential action of VAMP7 may partially "estrogenize" males and subtly reduce AR action, leading to slightly feminized male reproductive development in *VAMP7* BAC mice. This observation provides a molecular explanation for the clinical picture phenotype found in our cohort of human patients with genitourinary anomalies.

Focal disruption of spermatogenesis and reduced fertility in mice with elevated levels of VAMP7 {#S8}
-----------------------------------------------------------------------------------------------

Since androgen and estrogen action are also important for spermatogenesis, we examined 6-month-old male mice with elevated levels of VAMP7. Transgenic animals had small testes and focal spermatogenic deficiency resulting in subfertility ([Fig. 6](#F6){ref-type="fig"} and [Supplemental Fig. S4b--h](#SD1){ref-type="supplementary-material"}). Testis weight was reduced to about 50% compared to that of wild-type scrotal testes ([Fig. 6a](#F6){ref-type="fig"}). Epididymal and seminal vesicle weights were similar to those of wild-type controls ([Fig. 6b--c](#F6){ref-type="fig"} and [Supplemental Fig. S4c--d](#SD1){ref-type="supplementary-material"}). The histological pattern of the adult mouse cryptorchid testes was less uniform, showing discrete foci of disrupted spermatogenesis. Arrest of spermatogenesis, sloughing of germ cells at various stages of maturation, and vacuolization of Sertoli cells were evident within the affected seminiferous tubules ([Fig. 6d](#F6){ref-type="fig"} and [Supplemental Fig. S4e](#SD1){ref-type="supplementary-material"}). Large multinucleated round cells were often present in the lumen of the tubules ([Fig. 6d](#F6){ref-type="fig"} and [Supplemental Fig. S4e](#SD1){ref-type="supplementary-material"}). Serum testosterone, 17β estradiol, Lh, and Fsh levels were not significantly different from those in wild-type males ([Fig. 6e--h](#F6){ref-type="fig"} and [Supplemental Fig. S4f](#SD1){ref-type="supplementary-material"}). To quantify the functional consequences of the damage to the seminiferous epithelium, we measured sperm count and motility ([Fig. 6i](#F6){ref-type="fig"} and [Supplemental Fig. S4g](#SD1){ref-type="supplementary-material"}). Although the number of caudal sperm was not significantly decreased, the total motility of sperm isolated from caudal epididymes of 6-month-old *VAMP7* transgenic mice was reduced by 75% for strain 7 and 70% for strain 21, suggesting deficient epididymal function, perhaps due to altered hormone action ([Fig. 6i](#F6){ref-type="fig"} and [Supplemental Fig. S4g](#SD1){ref-type="supplementary-material"}). Histological examination of *VAMP7* BAC male reproductive tissues revealed morphological alterations of the epididymis in mutant mice, including vacuolization of the epididymal epithelium as well as the presence of numerous round cells in the lumen of caput and cauda V7BAC epididymides ([Fig. 6d](#F6){ref-type="fig"} and [Supplemental Fig. S4e](#SD1){ref-type="supplementary-material"}). To assess whether the reduced motility of caudal sperm from the transgenic males was associated with reduced fertility, a controlled mating experiment was conducted in which four to five 6-week-old WT or transgenic males were mated with 8-week-old WT females. During a 4-month period, *VAMP7* males sired a number of litters similar to those of the WT mice. However, the litter size in the transgenic group was significantly smaller ([Fig. 6j](#F6){ref-type="fig"} and [Supplemental Fig. S4h](#SD1){ref-type="supplementary-material"}).

In conclusion, *VAMP7* transgenic male mice exhibited complex disturbances of reproductive development and function, characterized by multiple structural and functional abnormalities of the reproductive system. These changes may result from combined effects of a persistent intra-abdominal location of the testes, as well as from the prolonged imbalance of estrogen and androgen action, because several of the abnormalities observed resemble those described in mice with prenatal exposure to exogenous estrogens.

DISCUSSION {#S9}
==========

Copy-number variants account for significant human phenotypic variation and disease risk^[@R43]^. They exert their influence by modifying the expression of genes mapping within or close to the rearranged regions. A *de novo* copy number variant in 46,XY patients with mild masculinization defects suggested a causal link of *VAMP7* gene duplication to the congenital genitourinary defects. Importantly, no copy number gain of *VAMP7* was found in 8,951 control individuals, highlighting the high degree of significance for the *VAMP7* copy number duplications and the strong association of *VAMP7* gene dosage changes to human cryptorchidism, hypospadias, and micropenis (*P* value = 2.2×10^−3^; Exact Fisher test). We initially detected a gain of *VAMP7* in 4 cases out of a total of 296 patients (i.e. 1.35%); then in a second replication study, we found 1 case in 28 distinct primary cultures of genital skin fibroblasts (3.6%). The incidence of *VAMP7* gains represents the highest frequency reported to date for a genetic/genomic cause of genitourinary birth defects. Even previously identified pathogenetic mutations in genes such as *INSL3, RXFP2*, and *AR* exhibited lower frequencies ranging from 0.3 to 0.8% in patients with disorders of sexual differentiation^[@R44]^. Additionally, the Gene Expression Omnibus database repository of high throughput gene expression data (<http://www.ncbi.nlm.nih.gov/geo/>) shows that *VAMP7* mRNA levels were significantly upregulated in human cryptorchid testes in two independent studies (GSE16191 and GSE25518)^[@R45],[@R46]^. These data strongly substantiate our findings and support the fact that *VAMP7* copy number change is a clinically significant factor in the etiology of human congenital genitourinary defects.

While our data supported a genomic basis of genitourinary birth defects, it also shed light on an unexpected molecular determinant impacting male phenotypic development. Under normal conditions, the vesicle trafficking protein, VAMP7, ensures proper membrane fusion and transport between various organelles^[@R12],[@R13],[@R22]^. This study shows that *VAMP7* is a dosage-sensitive gene, as slight differences in the magnitude of the phenotypic defects were present between the two *VAMP7* BAC transgenic lines. Indeed, line 7 mice, which had a higher level of *VAMP7* expression than line 21, exhibited a higher incidence of bilateral cryptorchidism, as well as a slightly more marked decrease of testis weight and litter size, than line 21. Similarly, line 7 displayed a significant up-regulation of distinct mRNA levels (with *Atf3, Sult1e1*, and *Cyr61* showing the most striking differences, and *Ctgf* and *Nrip1* revealing modest impairment). Mice from strain 21 also displayed a significant up-regulation of *Atf3* and *Sult1e1* and a trend of increase of *Cyr61* (*P* value = 0.09) while expression of *Ctgf* and *Nrip1* genes was unchanged. Our observations provide evidence that higher protein levels of VAMP7 correlate with a more severe phenotype in mice.

Elevated levels of VAMP7 enhanced estrogen receptor-driven transcription of genes including *Atf3, Ctgf*, and *Cyr61*, all of which are up-regulated in patients with hypospadias^[@R29]^. The dual function in membrane sorting and transcriptional action was previously reported for a subset of factors involved in endocytosis and endosomal trafficking such as Huntingtin interacting protein 1 (HIP-1), Auxilin 2, Clathrin heavy chain, β-Arrestin 1 and 2, APPL1 and 2 (adaptor protein containing PH domain, PTB domain and leucine zipper motif 1 and 2) and CALM (clathrin assembly protein lymphoid myeloid)^[@R47]--[@R51]^. Several of these endocytic proteins exert AR coregulatory characteristics^[@R47]--[@R49]^, mainly through association with transcriptional factors and/or facilitation of chromatin modifications^[@R47],[@R50],[@R52]^. Our study reinforces the concept that vesicular transport and endosomal factors are able to perturb key nuclear functions and transcriptional regulation.

We demonstrated that elevated levels of VAMP7 can lead to an increase of ligand-dependent ESR1 protein content without affecting its mRNA levels and can result in a subsequent stimulation of transcriptional activity similar to the action of other previously reported proteins^[@R53]^. ESR1 stability and protein turnover are finely controlled by ubiquitination and proteosomal degradation to ensure efficient transcriptional activity of the nuclear receptor^[@R54]--[@R56]^. Recent evidence highlights the existence of cross talk between the ubiquitin-proteasome and autophagy-lysosome systems^[@R57]^. Perturbations in the flux through either pathway could affect the activity of the other system^[@R58]^. Since VAMP7 is a regulator of autophagosome formation^[@R17]^, it is tempting to speculate that one of the potential effects of increased VAMP7 might be the perturbation of the ubiquitin-proteasome pathway leading to abnormal processing of selective proteins including ESR1. Although beyond the scope of this present study, the exact underlying molecular mechanisms definitely merit further clarification.

In conclusion, genomic defects encompassing the gene encoding the vesicle SNARE, VAMP7, are present in a subset of human patients with congenital genitourinary disorders. Alterations of the gene dosage of this vesicular trafficking factor are responsible for abnormal human and murine male genitourinary tract development, mainly due to a marked enhancement of estrogen receptor transcriptional action. VAMP7 overexpression underlies the etiology of a subset of common disorders of male sexual differentiation.

ONLINE METHODS {#S10}
==============

Ethics statement, human subjects, and sample collection {#S11}
-------------------------------------------------------

This study was approved by the Institutional Review Board Committee at the Baylor College of Medicine (Houston, TX, USA). Probands affected with idiopathic cryptorchidism and/or hypospadias were enrolled through Texas Children's Hospital and Ben Taub General Hospital, (Houston, TX, USA). Known causes of these birth defects, such as anomalies in the synthesis of testosterone or adrenal steroid hormones or exogenous modifiers, or karyotypic abnormalities were excluded etiologies after examination by pediatric urologists and/or neonatologists. Written informed assents were obtained for infant/child subjects and consents from their parents. Blood was collected from the children during surgery for correction of cryptorchidism or hypospadias. Parents provided saliva specimens for DNA isolation. Primary cultures of genital skin fibroblasts (GSF) isolated from the foreskin of male neonates at the time of circumcision or surgical correction were obtained from patients with hypospadias and/or cryptorchidism, after obtaining approval from the Baylor College of Medicine Institutional Review Board (Houston, TX, USA). GSF cell lines were maintained in MEM with 10% FBS and 1% penicillin and streptomycin.

CGH-based Microarray Analysis (CMA) {#S12}
-----------------------------------

High molecular weight genomic DNA isolated from peripheral blood or saliva was submitted for chromosomal microarray analysis (CMA) to the Clinical Cytogenetics Laboratory at Baylor College of Medicine. CMA is a clinically-validated targeted CGH array that covers over 150 distinct human clinically relevant chromosomal loci (<http://www.bcm.edu/geneticlabs/?pmid=16207>). CMA V6 OLIGO microarray, a custom-targeted array manufactured by Agilent Technologies (Santa Clara, CA) using approximately 44,000 oligonucleotides to emulate the CMA V6 BAC arrays^[@R59]^ was used. CMA procedures and data analyses using an in-house analysis package for copy number analysis were used as described previously^[@R60]^. One unique DNA reference served as a control for CMA analysis and was from a pregnancy-proven fertile, gender-matched individual without any familial history of congenital genitourinary defects. The presence of imbalances was quantified by calculating the ratio of signal intensities of test DNA from patients compared with reference DNA extracted from a pregnancy-proven fertile, gender-matched individual with no familial history of congenital genitourinary defects. The log~2~ (Cy5/Cy3) scaling has the consequence of centering the ratios at approximately zero, making DNA copy number gains appear positive (positive shift of the probes signal).

FISH analysis {#S13}
-------------

The BAC clone of interest (RP11-479B17) and a control probe RP11-815E21 (at Xq22.3) were grown in TB media with 20 mg ml^−1^ chloramphenicol. DNA was extracted from the BAC clones (Eppendorf Plasmid Mini Prep kit, Hamburg, Germany), directly labeled with fluorochrome conjugated-dUTP by nick translation (Vysis, Downer Grove, IL) according to the manufacturer's instructions, and hybridized to PHA-stimulated patient lymphocyte cultures. Digital FISH images were captured using MacProbe version 4.4 software (Applied Imaging, San Jose, CA).

CNV Taqman assays {#S14}
-----------------

Copy Number Variant TaqMan® assays (Applied Biosystems) custom designed for *VAMP7*, were performed according to the manufacturer's protocol using One Step Plus Real-Time PCR. TaqMan® Copy Number Reference Assay *RNase P* was used as the standard reference assay for copy number analysis. Relative quantitation analysis was done to estimate copy numbers for each sample by using the Copy-Caller-Software, v.1.0 (Applied Biosystems, Grand Island, NY, USA).

Cell culture and transfections {#S15}
------------------------------

For transfection experiments, HeLa cells were grown in DME without phenol red, in the presence of 10% stripped fetal calf serum. Cells were plated at 70% confluency in 6-well plates for luciferase assays or 50% for immunofluorescence. Cells were transfected with several reporter-gene plasmids containing either the androgen responsive element of PSA promoter or a multimerized *ERE* sequence. These constructs were co-transfected as indicated in each experiment with different expression vectors encoding VAMP7 in pCMV6-XL5 vector (Origene, Rockville, MD) as well as PCMV-AR and PCR3.1-ESR1. Treatment with 10^−8^ M DHT or 17β estradiol was done 24 h after transfection, and reporter-gene levels were determined 24 hours after hormonal induction using Promega reagents.

For knock-down experiments, NT2/D1 (ATCC CRL-1973) cells were grown in a modified Dulbecco\'s medium supplemented with 10% fetal bovine serum and L-glutamine in an atmosphere of 5% CO2. Cells were plated in 6-well plates (1 × 10^5^ per well) for RNA extraction. The next day, cells were transfected for 72 hours with nonspecific (Scramble) or siRNA for human VAMP7 (Dharmacon, Lafayette, CO, USA) according to the manufacturer's procedure.

Immunofluorescence {#S16}
------------------

Cells were rinsed twice in ice-cold phosphate-buffered saline (PBS) and fixed with a freshly prepared solution of 4% paraformaldehyde in PBS for 20 minutes and permeabilized for 10 minutes with 0.1% digitonin in PBS. After several rinses in ice-cold PBS, cells were incubated in 3% normal goat serum in PBS (blocking solution) for 30 minutes at room temperature, followed by an overnight incubation at 4°C with primary antibodies. Cells were extensively washed with PBS-0.1% digitonin and then incubated with Alexa-conjugated secondary antibodies (Molecular Probes) for 60 minutes at room temperature. Coverslips were mounted in a mounting medium. Images were captured with an API Delta Vision deconvolution microscope using SoftWorx software (Applied Precision, Issaquah, Washington, USA). Primary antibodies used were anti-AR (Sc-816, 1:200, Santa Cruz Biotechnology Inc.), anti-VAMP7 (NB100-91356, 1:1,000, Novus Biologicals), ESR1 (MA1-310, 1:200, Thermo-Fisher) and anti-RAB5 (\#2143, 1:100, Cell Signaling).

Quantitative RT-PCR analysis {#S17}
----------------------------

Total RNA was purified using the RNeasy Kit including an optional DNase I treatment according to the manufacturer\'s instructions (Qiagen). cDNA was prepared from 500 ng of total RNA by reverse transcription. Real-time PCR was performed with TaqMan PCR Master Mix on an ABI StepOnePlus Realtime PCR System (Applied Biosystems). PCR conditions were: 50°C for 2 min, 94°C for 2 min, followed by 40 cycles of 94°C for 15 s and 60°C for 30 s. For each experimental sample, the relative abundance value was normalized to the value derived from the endogenous control (*GAPDH*) of the same sample. Relative mRNA levels were quantified by the comparative DDCT method.

Generation of *VAMP7* BAC transgenic mice {#S18}
-----------------------------------------

All described procedures were approved by the Institutional Animal Care and Use Committee of Baylor College of Medicine (Houston, TX, USA) and conducted in compliance with the Guide for the Care and Use of Laboratory Animals in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). BAC (RP11-479B17) containing human *VAMP7* gene was purified using the NucleoBond BAC 100 Kit (Clontech). The purified transgene DNA was introduced into the pronuclei of fertilized oocytes from the FVB/N mice through the service of Genetically Engineered Mouse Core Facility at the Baylor College of Medicine (<http://cb-apps01.cellb.bcm.tmc.edu/gemcore/home.htm>).

Fertility studies and semen evaluation {#S19}
--------------------------------------

The fertility and fecundity of 6-week-old FVB male *VAMP7* and their WT littermates were determined in a continuous mating study in which each male was mated with two FVB wild type females (6 weeks of age) for 4 months. The females were monitored for pregnancy during and after the mating periods, and the number of litters and offspring was recorded. Penile length was measured after exposing the penis up to the ischial arch and its stretched length measured from the tip of the glans penis to the midpoint of the ischial arch. The cauda epididymides of 3- to 8-month-old V7BAC and WT mice were collected in M2 medium. Cuts were made and sperm were allowed to swim out into the medium for 15 min at 37°C temperature. Motility was manually assessed using a hemocytometer.

Hormone assays {#S20}
--------------

Mice under anesthesia were exsanguinated by closed cardiac puncture. Serum samples were collected and stored frozen at −20°C until further use. RIAs for LH and FSH were performed using National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) hormone assay kits according to the standard protocols of the Ligand Assay and Analysis Core Laboratory (University of Virginia, Charlottesville, VA, USA).

Histological analysis {#S21}
---------------------

Bouin's fixed, paraffin-embedded testes were cut in cross and longitudinal sections and stained with hematoxylin and eosin. For immunohistochemistry analysis, slides of paraffin-embedded samples were deparaffinized and dehydrated. Antigen retrieval was performed by heat inactivation in 0.1 M sodium citrate for 30 min. VAMP7 (HPA036733, 1:25, Sigma Prestige or NB100-91356, 1:200, Novus Biologicals), AR (sc-816, 1:200, Santa Cruz), ATF3 (sc-188, 1:400, Santa Cruz), FKBP5 (AF4094, 1:200, R&D Systems), MAFB (ABE55, 1:200, Millipore), and desmin (NB110-56931, 1:500, Novus Biologicals) primary antibodies were used for immunodetection. The staining was performed using the avidin-biotin peroxidase system (ABC-peroxidase), and positive signals were visualized as brown precipitates using 3,3\'-diaminobenzidine tetra-hydrochloride. Control staining was conducted by omission of the primary antibody. Hematoxylin was used for counterstaining.

Western blot and co-immunoprecipitation {#S22}
---------------------------------------

20 µg of protein aliquots from cell lysates of testis from V7BAC transgenic mice were separated by 15% SDS-PAGE and transferred to nitrocellulose membranes. The membranes were probed with primary antibodies against VAMP7 (sc-166394, 1:100, Santa-Cruz or sc-67060, 1:50, Santa-Cruz), AR (sc-816, 1:1,000, Santa-Cruz), ESR1 (MA1-310, 1:200, Thermo-Fisher), LMNA (sc-20681, 1:200, Santa-Cruz), GAPDH (sc-32233, 1:200, Santa-Cruz), and ACTB (AC-40, 1:5,000, Sigma). HeLa cells were cotransfected with AR or ESR1 or VAMP7 or in combination. After 24 h of overexpression, cell lysates were prepared and immunoprecipitation was carried out using antibodies raised against AR (sc-816, Santa-Cruz) or ESR1 (MA5-13065, Thermo-Fisher) or VAMP7 (sc-67060, Santa-Cruz) or control IgG antibody. The samples were later subjected to western blotting with the indicated antibodies. Input was 5% of the lysates.

Chromatin immunoprecipitation {#S23}
-----------------------------

*In vivo* ChIP was performed on single-cell collagenase-treated testis from VAMP7 mutant mice. Formaldehyde (1%) was added to produce cross-linking during 10 minutes at room temperature. The rest of the ChIP procedure was performed using the EZ ChIP kit (Millipore) following the manufacturer's protocol. AR antibody was from Santa-Cruz (sc-816, Santa-Cruz). qPCR for ChIP was performed using the SYBR-Green technology (Applied Biosystems). Results were normalized to input in each case. Primer sequences are available upon request.

Gene expression microarray hybridization and analysis {#S24}
-----------------------------------------------------

NT2/D1 (ATCC CRL-1973) cells were grown in a modified Dulbecco\'s medium supplemented with 10% fetal bovine serum and L-glutamine in an atmosphere of 5% CO2. Cells were plated in 6-well plates (1 × 10^5^/well) for RNA extraction. The next day, cells were transfected for 72 hours with non-specific (scramble) or siRNA for human *VAMP7* (Dharmacon, Lafayette, CO, USA) according to the manufacturer's procedure. Three samples treated with siRNA targeting *VAMP7* in NT2 cells were compared with three samples of cells treated with scrambled siRNA using Affymetrix Human U133 2.0 Plus Array which contains 1,300,000 unique oligonucleotides 47,000 transcripts and variants which represent about 39,000 of the best characterized human genes. The probe set design was based on databases: GenBank, dbEST, RefSeq. Microarray results were normalized using Robust Multichip Average (RMA). Statistical analysis approach of SAM (Significance Analysis of Microarray) was applied using Multiple Experiment Viewer (MeV). Data have been deposited in the GEO database under the accession number: GSE56102. We identified a list of about 600 genes that are significantly altered at a 20% False Discovery Rate (FDR) when *VAMP7* was knocked down in NT2/D1 cells. This list was then analyzed using Ingenuity Pathway Analysis (IPA) to identify pathways and biological functions involved.

Accession number {#S25}
----------------

Gene expression microarray data have been deposited in the GEO database. Accession number: GSE56102.

Statistical analysis {#S26}
--------------------

Samples and animals were evaluated in a randomized manner by six investigators (M.T.L.; S.H.; J.F.L.; B.Z; K.R. and J.A.) who were blinded to the treatment conditions. No statistical method was used to predetermine sample size for animal or cell studies. No inclusion/exclusion criteria were defined for samples and animals. At least 3 independent experiments were performed for mouse tissues and cell lines and included in the statistical analyses, as reported in all figure legends. Each replicate represents an independent experiment. Data are presented as means ± s.e.m. One- or two-way analysis of variance (ANOVA) with *post hoc* Bonferroni test was run for all statistical analyses except where a Student\'s *t*-test was used. Significance threshold was set at *P* = 5.0 × 10^−2^. To analyze the frequency of *de novo* Xq28 copy number change in affected GU patients compared to unaffected GU individuals (non-GU controls), two-tailed Fisher\'s exact test was performed and statistical significance determined using SPSS software.
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![A terminal Xq28 gain encompassing *VAMP7* in 46,XY children presenting with masculinization disorders of the urogenital tract. (**a,b**) Genomic hybridization profiles of unrelated 46,XY subjects with cryptorchidism or hypospadias compared with a gender-matched reference DNA. The mean log~2~ ratio (patient/reference) of intensity for each single probe is presented across individual chromosomes. Arrows indicate a terminal X copy gain (green). (**c**) Representative FISH hybridization of PHA-stimulated blood lymphocytes from Xq28 CGH array-detected patients using RP11-479B17 probe (red), specific to the pseudo-autosomal region 2, including Xq28 and Yq12 loci. RP11-815E21 at Xq22.3 (green) was used as a hybridization control. White arrow indicates copy number gain. Scale bar, 5 µm. (**d**) Literature review of patients with Xq28 duplication encompassing *VAMP7* and presenting with defective virilization of the male reproductive tract. *For references, see* [Supplemental Table 1](#SD1){ref-type="supplementary-material"}.](nihms589175f1){#F1}

![VAMP7 is present in human and murine male reproductive tissues. (**a**) Western-blot analysis of VAMP7 expression in human fetal testes and whole ovarian lysates. ACTB (β actin) was used a loading control. (**b**) qRT-PCR analysis of *VAMP7* mRNA levels normalized to *GAPDH* in human adult tissues. *n* = 6 independent samples for each tissue. Data are presented as means ± s.e.m. (**c--e**) Immunohistological detection of VAMP7 in normal human adult testicular (**c**) and penile tissues including urethral (**d**) and preputial (**e**) epithelia. Scale bar, 125 µm. (**f,g**) Immunohistochemical detection of VAMP7 expression in fetal testis (**f**) and external genitalia (**g**) from wild-type male mice at embryonic stage E16.5. Scale bar, 125 µm.](nihms589175f2){#F2}

![Mice overexpressing VAMP7 exhibit cryptorchidism and abnormal external genitalia. (**a**) qRT-PCR analysis of *VAMP7* mRNA levels normalized to *Gapdh* in testis from WT (*n* = 4 animals) and humanized transgenic V7BAC mice (*n* = 5 mice for line 7 and *n* = 4 mice for line 21) using primers common to both mouse and human *VAMP7* transcripts. Data are presented as means ± s.e.m. **(b)** VAMP7 immunohistological staining of fetal and adult testicular tissue and external genitalia from V7BAC transgenic and WT mice. Scale bars, 125 µm. For fetal genital tubercles, scale bar, 500 µm. **(c)**Distribution of unilateral and bilateral cryptorchidism in V7BAC transgenic mice harboring undescended testes. (*n* = 7 cryptorchid animals for each line). **(d)** Anatomical locations of cryptorchid testes in *VAMP7* transgenic mice (*n* = 14 cryptorchid testes for each line). Distribution is presented in percentage. **(e)** Representative pictures of testis position in V7BAC and WT mice. B: bladder; T: testis; Epid. fat: epidydimal fat. Scale bar, 1 cm. (**f**) Desmin staining of testis and gubernaculum of V7BAC and WT male embryos at gestational age E18.5. Arrows indicate the gubernaculum cord. Scale bar, 500 µm. (**g**) Hematoxylin-eosin staining of cross-sections of genital tubercles from V7BAC male mouse embryos at gestational age E18.5 (*n* = 6) and WT littermates. Asterisks indicate normal and abnormal fusion of urethral folds or hypospadias, while arrows show abnormalities of the epithelial-lined prepuce housing the penis. The occurrence of penile defects was presented in percentage. Scale bar, 150 µm. (**h**) Measurement of anogenital distance in *VAMP7* transgenic adult male mice (*n* = 9) and WT littermates (*n* = 5). Data are presented as means ± s.e.m. (**i**) Measurement of penile length in *VAMP7* mutant adult male mice (*n* = 5) compared to WT animals (*n* = 7). Data are presented as means ± s.e.m. Mean differences were determined by unpaired, two-tailed Student's *t*-test. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001.](nihms589175f3){#F3}

![Elevated levels of VAMP7 modestly impair AR function. (**a**) Luciferase assays in HeLa cells co-transfected with VAMP7 or VAMP7 and AR and incubated in absence (EtOH) or in presence of 10^−8^ M dihydrotestosterone (DHT) for 24 h. *n* = 3 independent experiments for each condition. Data are presented as means ± s.e.m. One-way analysis of variance (ANOVA) with *post hoc* Bonferroni test was used for statistical analyses. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. (**b**) Reciprocal co-immunoprecipitation of AR and VAMP7 following their co-transfection in HeLa cells.(**c**) Immunofluorescence staining of VAMP7, AR, and RAB5 in HeLa cells after transfection with AR, VAMP7, or both, upon stimulation with ethanol (EtOH) or 10^−8^ M dihydrotestosterone (DHT) for 24 h. Scale bar, 5 µm. (**d**) AR immunostaining of adult testis from V7BAC or WT mice. Arrows indicate cytoplasmic staining. Scale bar, 125 µm (Inset, 25 µm). (**e**) *In vivo* chromatin immunoprecipitation assays of testicular lysates from WT (*n* = 3) and V7BAC (*n* = 3) mice using IgG or AR antibody followed by qPCR of *Fkbp5*, *Mafb* and *Fkbp4* promoters. Data are presented as means ± s.e.m. Two-way analysis of variance with *post hoc* Bonferroni test was used for statistical analyses. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. (**f,g**) Immunostaining of Fkbp5 (**f**) and Mafb (**g**) in fetal and adult external genitalia and testis of WT and V7BAC mouse embryos (E18.5). For fetal tissues: scale bar, 250 µm. For adult urethra and testis: scale bar, 100 µm.](nihms589175f4){#F4}

![VAMP7 enhances estrogen receptor transcriptional activity. (**a**) Luciferase assays following transfection with VAMP7 or ESR1 or VAMP7 and ESR1 in HeLa cells incubated in absence (EtOH) or presence of 17 beta-estradiol (10^−8^ M) for 24 h. *n* = 3 independent experiments for each condition. Data are presented as means ± s.e.m. One-way analysis of variance (ANOVA) with *post hoc* Bonferroni test was used for statistical analyses. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. (**b**) Western Blot analysis of ESR1 and LMNA (lamin A/C) in nuclear protein extracts of HeLa cells co-transfected with ESR1 or ESR1 and VAMP7 in absence (EtOH) or presence of 17 beta-estradiol (10^−8^ M) for 24 h. (**c**) Reciprocal co-immunoprecipitation of ESR1 and VAMP7 following their co-transfection in HeLa cells. (**d**) qRT-PCR analysis of key genes of ESR1 signaling in testis from WT (*n* = 3) and V7BAC mice (line 7; *n* = 3). Data are expressed as mean ± s.e.m. Mean differences between WT and V7BAC were determined by unpaired, two-tailed Student's *t*-test. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. (**e**) ATF3 immunostaining of testis and external genitalia at fetal and adult stages of WT and V7BAC mice. For fetal tissues: scale bar, 250 µm. For adult urethra and testis: scale bar, 100 µm. (**f**) qRT-PCR of *VAMP*7 and *ATF3* gene expression after incubation with non-targeting (scramble) or *VAMP7* siRNA in NT2/D1. *n* = 3 independent experiments for each condition. Mean differences were determined by unpaired, two-tailed Student's *t*-test. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. (**g**) Left: Heatmap of testis gene expression profiles in NT2/D1 transiently transfected with non-targeting (scramble) or *VAMP7*-specific siRNA. Yellow and blue colors indicate increased and decreased expression, respectively, relative to scramble. Right: Ingenuity Pathway Analysis (IPA 8.5) top canonical pathways significantly altered (20% FDR) after *VAMP7* knockdown in NT2/D1 cells. (**i**) Pictures of inguinal hernia in V7BAC males and hematoxylin-eosin staining of extensive granulomatous inflammatory response of entrapped tissues. Scale bar, 100 µm (**j**) Schematic representation of VAMP7 impact on estrogen receptor signaling and male phenotypic development.](nihms589175f5){#F5}

![Abnormal spermatogenesis and reduced motility and fertility in *VAMP7* transgenic mice. (**a**) Weights of cryptorchid gonads (*n* = 7) from 6-month-old male V7BAC and scrotal testis (*n* = 8) from WT littermates. (**b,c**) Epididymis and seminal vesicles weights from 6-month-old male V7BAC (*n* = 8 mice) and WT (*n* = 6 animals). (**d**) Hematoxylin-eosin stained images of paraffin-embedded testis and caput and cauda epididymides sections from 6-month-old WT and V7BAC mice. Scale bar, 125 µm. (**e--h**) Serum testosterone, 17 beta-estradiol, Lh and Fsh hormone levels in 6-month-old male V7BAC and WT mice. **(i)** Epidydimal sperm count and motility in 6-month-old WT (*n* = 6) and V7BAC (*n* = 5) mice. **(l)** Litter size from WT (*n* = 12 litters) and V7BAC (*n* = 16 litters) male mice in a 4 month -continuous mating study. All data are expressed as mean ± s.e.m. Statistical significance was determined by unpaired, two-tailed Student's *t*-test. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001.](nihms589175f6){#F6}
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